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Abstract
Schistosomiasis is among the most prevalent parasitic infections worldwide. However, current Global Burden of Disease (GBD)
disability-adjusted life year estimates indicate that its population-level impact is negligible. Recent studies suggest that GBD
methodologies may significantly underestimate the burden of parasitic diseases, including schistosomiasis. Furthermore, strain-
specific disability weights have not been established for schistosomiasis, and the magnitude of human disease burden due to
Schistosoma japonicum remains controversial. We used a decision model to quantify an alternative disability weight estimate of
the burden of human disease due to S. japonicum.W er e v i e w e dS. japonicum morbidity data, and constructed decision trees for
all infected persons and two age-specific strata, ,15 years (y) and $15 y. We conducted stochastic and probabilistic sensitivity
analyses for each model. Infection withS.japonicum was associated withanaverage disabilityweight of 0.132,withage-specific
disability weights of 0.098 (,15 y) and 0.186 ($15 y). Re-estimated disability weights were seven to 46 times greater than
current GBD measures; no simulations produced disability weight estimates lower than 0.009. Nutritional morbidities had the
greatestcontributiontotheS.japonicumdisabilityweightin the,15 ymodel,whereasmajororganpathologieswerethemost
critical variables in the older age group. GBD disability weights for schistosomiasis urgently need to be revised, and species-
specific disability weights should be established. Even a marginal increase in current estimates would result in a substantial rise
in the estimated global burden of schistosomiasis, and have considerable implications for public health prioritization and
resource allocation for schistosomiasis research, monitoring, and control.
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Introduction
Schistosomiasis is one of the most prevalent parasitic infections
worldwide. An estimated 779 million people are at risk for
schistosomiasis, with 207 million infected in 76 countries and
territories [1,2]. Approximately 120 million people are symptom-
atic and 20 million have severe and debilitating disease [3–5].
Schistosomiasis accounts for 1.7 [6,7] to 4.5 million disability-
adjusted life years (DALYs) [8] lost each year worldwide, among
the highest of all neglected tropical diseases.
Schistosomiasis japonica is caused by the trematode Schistosoma
japonicum. Schistosome egg deposition in tissue and subsequent
inflammatory immune response result in extensive clinical
manifestations, including hepatomegaly, splenomegaly, and liver
fibrosis [9–16], as well as ‘‘subtle’’ morbidities such as anemia,
diarrhea, growth retardation, and cognitive deficits [10,17–21].
Schistosomiasis japonica may be more pathogenic compared to
other schistosomes affecting humans, due to comparatively higher
egg production [22]. However, the burden of human disease due
to S. japonicum infection is not well-established.
Global Burden of Disease (GBD) estimates indicate that the
population-level impact of schistosomiasis is negligible. Schisto-
somiasis accounts for only 0.1% of the global burden of disease
[23]. A major limitation of the GBD burden estimates for
schistosomiasis is their restriction to the period of acute infection,
excluding a number of chronic, severe, and debilitating
morbidities, such as liver cirrhosis and cognitive deficits, which
were included in disability estimations for other infections. As a
result, age-specific GBD disability weights were estimated to be
0.005 for those ,15 years (y) of age and 0.006 for those $15 y,
on a scale from 0 (no impairment) to 1 (death) [8,17,19,24].
Similar GBD weights have been assigned to relatively minor
conditions such as facial vitiligo [8,17,19,24]. In contrast, some
studies [19,24] have suggested that the actual burden of
schistosomiasis is several-fold higher than current GBD estimates
[8,17,19,24]. For example, a recent systematic review and meta-
analysis of all schistosome strains [19] and a community-based
study of chronic schistosomiasis japonica in China [16] concluded
that the GBD disability weights underestimate the extent of
disability due to schistosomiasis; re-estimated disability weights for
www.plosntds.org 1 2008 | Volume 2 | Issue 3 | e158schistosomiasis were four to 30 times higher than current GBD
measures [19,23,25–27].
Another limitation of the GBD study [23,25–27] and subse-
quent schistosomiasis burden assessments [19,24] was their
estimation of disability weights for all three major schistosome
species (S. japonicum, S. mansoni and S. haematobium) together, despite
their distinct pathophysiology and associated morbidities. A recent
community-based study in China using a standard quality of life
measurement scale (EuroQol) suggested that species-specific
estimation of disability weights for schistosomiasis is warranted,
and that GBD values aggregated across all schistosome species
may underestimate the disability associated with S. japonicum [16].
However, this study excluded nutritional and neurological
morbidities, and may therefore still underestimate the burden of
human disease due to S. japonicum infection.
The burden of schistosomiasis has not been re-examined in over a
decade, despite three revisions to the GBD study [25–27] and a
strong recommendation from the World Health Organization
(WHO) [8]. Additionally, there is a lack of international consensus
in disease burden assessment criteria, disability weights, and
estimated burden for schistosomiasis. For example, in 2002, a
WHO Technical Report recalculated the global burden of
schistosomiasis at 4.5 million DALYs, and asserted that the previous
estimate of 1.7 million DALYs lost to schistosomiasis (2001)
‘‘represents a serious underestimate and should be revised’’ [8].
However, the WHO continues to report the 1.7 million DALYs
figure from 2001 [6,7]. Further, there is a more than ten-fold
difference between GBD and WHO estimates for schistosomiasis-
related mortality, or 15,000 to 280,000 deaths per year [8,23].
At present, no global species-specific burden assessment exists
for schistosomiasis. The burden due to S. japonicum remains
controversial and warrants further investigation. This study was
conducted to quantify age-specific disability weight estimates for
the burden of human disease due to S. japonicum infection using a
decision model approach.
Methods
Literature Search Strategy
We conducted a structured literature search using MEDLINE
electronic database to identify published studies from Jan 1, 1966
to May 1, 2007. A detailed summary of key words and search
headings are provided in Appendix S1. Additional sources were
identified from bibliographies of published studies, hand searches
of scientific meeting abstracts, expert committee reports, and
unpublished manuscripts and theses at Brown University, United
States. We also solicited unpublished studies from known
schistosomiasis japonica researchers via e-mail to minimize
publication bias. These sources were retrieved, collected, indexed,
and assessed for morbidity and disability outcome data.
The initial inclusion criteria for this review were the availability
of an abstract and a focus on human infection with schistosomiasis.
The abstracts of all remaining studies were reviewed and the
following inclusion criteria were applied: (i) focus on S. japonicum;
(ii) human studies; (iii) experimental or observational (treatment,
morbidity) study designs; and (iv) description of S. japonicum
morbidity measures and their respective prevalences and/or
disability weights (Figure 1). Additional information on publica-
tion date, author, location, population, study type, and relevant
outcomes were recorded. Where available, we collected morbidity
estimates based upon standardized clinical physiological data and
WHO diagnostic criteria [28] such as grades I through III clinical
classification for hepatic fibrosis and cirrhosis [29] or Hackett
score $2 to define splenomegaly [30]. Although major organ
pathologies such as hepatic and spleen morbidities have not been
extensively studied in schistosomiasis, these morbidities were
included as disability-related outcomes in the GBD disease burden
assessment for other conditions. We included these morbidities in
this assessment of disability-related outcomes in S. japonicum, based
on our a priori hypothesis that they may impose a heavy burden on
infected individuals.
Model Structure
We identified a broad spectrum of morbidities associated with S.
japonicum, namely: diarrhea, gastrointestinal bleeding, abdominal
pain, hepatomegaly (mild/moderate, severe), hepatic fibrosis and
cirrhosis (mild, moderate, severe), splenomegaly, cognitive deficits,
stunting, wasting, anemia (mild, moderate, severe), central nervous
system disease (i.e., including non-epilepsy neurological manifes-
tations), and epilepsy.
Decision trees were used to systematically combine a large
number of prevalence and disability data for S. japonicum morbidities
[31]. The disability weight for schistosomiasis was estimated in three
models to represent all ages, those aged ,15 y and those aged
$15 y, in order to facilitate comparison with the GBD study. For
each model, the disability weight was estimated as:
DisabilityWeight~
X N
A~1
PmorbidityA xD morbidityA
where PmorbidityA represents the probability of the A
th morbidity,
DmorbidityA represents the disability weight associated with the A
th
morbidity, and N is the total number of morbidities considered.
In general, we structured the decision trees to allow for all
plausible combinations of morbidities, with the presence or
absence of any single morbidity considered independently from
other morbidities, with the exception of liver morbidity. Our
model was therefore a series of successive binary branches, each
depicting the presence or absence of a single morbidity. This
means that although the probability of developing each morbidity
Author Summary
Schistosomiasis is a parasitic infection caused by a flatworm
that disproportionately affects the world’s poorest popu-
lations. Schistosomiasis is one of the most common
infections worldwide, affecting over 207 million people in
76 countries. Current international estimates indicate that
schistosomiasis has a minimal impact at the population
level. This has contributed to its low prioritization in global
health and subsequent resource allocation for disease
control. However, recent studies indicate that these
measures underestimate the extent of neglected tropical
diseases, including schistosomiasis. Despite World Health
Organization recommendations, the burden of schistoso-
miasis has not been re-examined in over a decade, and
there are no established estimates for different types of
schistosomiasis. The impact of symptoms associated with
the Asian strain, Schistosoma japonicum, remains contro-
versial. This study was conducted to provide an alternate
measure of the burden of S. japonicum. We reviewed the
literature and calculated a summary estimate for S.
japonicum which was seven to 46 times greater than
current measures for schistosomiasis. Findings suggest that
current measures severely underestimate the extent of
schistosomiasis, and urgently need to be revised. Further
research is needed to examine the burden of schistosomi-
asis and other forgotten tropical diseases affecting the
world’s poorest people in endemic countries.
Burden of Schistosomiasis Japonica
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could exceed 1.
Based on available hepatic pathophysiology data, we conserva-
tively structured the model to restrict liver pathologies according to
usual liver disease progression (i.e. hepatomegaly to fibrosis to
cirrhosis), and allow for the co-occurrence of only hepatomegaly
and fibrosis. This is because, as the disease progresses to more
severe pathology, the associated disability weight also increases.
Therefore, if a combination of several liver co-morbidities had
been allowed, the disability weight for liver disease could be
overestimated. Figure 2 illustrates the branch of the decision tree
for the liver pathologies.
Model Inputs
Probabilities. Prevalences of S. japonicum morbidities were
used as the measure of occurrence, instead of incidence rates, due
to the unavailability of incidence estimates and to allow
comparability with prior studies [19,23,25–27]. Since prevalence
is proportional to the incidence multiplied by the duration of the
morbidity, measures reflected in these model inputs represent a
combination of the time spent in a morbidity state and its actual
occurrence.
For each morbidity, the lowest prevalence estimate identified
from the literature was used as the average value of a beta (b)
distribution. The lowest estimates were systematically selected for
the lowest values, in order to undertake a highly conservative
approach and foster comparability of findings to the GBD study.
The range of each morbidity prevalence estimate reported in the
literature was used to represent the variance of the b distribution.
The b distribution was selected because it satisfied the a priori
requirements to restrict the probability estimate range between 0
and 1, and enabled calculation and summarization of available
prevalence data and the level of uncertainty associated with these
estimates [32].
Disability Weights. We examined the original and revised
GBD assessments to identify disability weights for morbidities
associated with S. japonicum [23,25–27]. For example, although
schistosome infection is the only sequela considered in the GBD
assessment for schistosomiasis, morbidities such as diarrhea,
anemia, cognitive deficits, and cirrhosis are available in burden
Figure 1. Literature search strategy. Shown is a diagrammatic representation of the retrieval strategy used for identifying and selecting studies
for inclusion in the final analysis.
doi:10.1371/journal.pntd.0000158.g001
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compiled these disability weight estimates, supplemented findings
with data derived from literature sources, and consulted experts
working on schistosomiasis japonica in countries where this disease
is endemic (e.g., the Philippines and China) and from the United
States, to confirm conservative proxy disability weight estimates.
For each morbidity, an approach similar to the one described for
the prevalence of each morbidity was used to represent the value
and uncertainty of the disability weights.
Base-Case Analyses
We calculated a baseline disability weight for each model using
the most conservative mean estimates for disability weight inputs
for all morbidities. We re-evaluated each model after systemati-
cally excluding each input to evaluate the independent contribu-
tion of each variable to the overall disability weight estimate.
Model inputs were considered critical variables if they contributed
more than 10% to the overall disability weight.
Sensitivity Analyses
One-way. We performed deterministic one-way sensitivity
analyses for each variable, for both probability and disability
weight inputs, in order to assess the degree to which variation in
each model input altered findings. We re-evaluated each model at
the lower and upper bounds of the 95% confidence interval (CI)
for each input, and observed subsequent modifications to the
model disability weight. Model inputs were considered critical
variables if alteration resulted in at least 10% change in the overall
disability weight.
Multi-way. We performed multi-way deterministic sensitivity
analyses to explore the most extreme values for disability weight
estimates in overall and age-specific models. In the conservative
and pessimistic scenarios, we simultaneously considered the
respective lower and upper bounds of the 95% CIs for all
probability and disability weight inputs, respectively.
Probabilistic. Deterministic analysis is typically limited in its
consideration of a small number of model inputs with fixed values.
Conversely, probabilistic analyses allow all inputs to vary
simultaneously according to their distributions. We performed
probabilistic sensitivity analyses with 5,000 Monte Carlo
simulations for each of the three models. In each simulation, the
value for each model input was selected at random from its
specified distribution. In each case, we obtained a probability
density distribution for schistosomiasis japonica disability weight.
We summarized the results across all simulations by graphing the
mean, standard deviation, and ranges of disability weights over
5,000 Monte Carlo analyses in each model [33].
Results
Model Inputs
The retrieval search strategy for study selection and details
regarding study inclusion and exclusion in this analysis are
diagrammatically represented in Figure 1. We identified 1093
potentially relevant studies from 1966 to May 1, 2007. We excluded
187 studies because no abstract was available. From the remaining
906 publications, 438 non-human studies were excluded, and 468
studies were retrieved for a detailed review. After careful
examination of thepublications, a total of 420 studies wereexcluded,
including: 42 additional non-human studies, 44 non-S. japonicum,3 2
case reports, 98 review articles, and 204 with no morbidity measure
linked to schistosomiasis and/or no useable information on
morbidity outcomes. A total of 48 studies met the inclusion criteria
for this assessment, including 34 primary publications and 14
secondary papers from the same studies (Figure 1).
Model Disability Weight
Base-Case Analyses. The average probability and disability
weight values used in the base-case analyses are provided in
Table 1. There were more publications investigating the
occurrence of schistosomiasis-associated diarrhea, anemia,
hepatomegaly, liver fibrosis, and splenomegaly, compared to
publications which examined schistosomiasis-associated nutritional
morbidities (e.g., wasting), cognitive function, cirrhosis, and
neurological manifestations.
Figure 2. Schematic representation of the model. Shown is the branch of the model depicting liver pathology, which may or may not be
present. If present, there may be hepatomegaly of varying degrees. Regardless of the degree of hepatomegaly, fibrosis may exist. Cirrhosis could only
occur when fibrosis was present. Other comorbidities did not depend on the presence of other conditions.
doi:10.1371/journal.pntd.0000158.g002
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www.plosntds.org 5 2008 | Volume 2 | Issue 3 | e158S. japonicum was associated with an average disability weight of
0.130 in the overall model, with age-specific disability weights of
0.098inthe ,15 y model and 0.198 for the $15 y model.Inthe all-
ages model, major organ pathologies contributed to the largest
proportion of the total disability weight, including probability and
disability weight estimates for mild/moderate and severe hepato-
megaly, mild fibrosis, mild cirrhosis, and splenomegaly (Table 2).
The contributions of the different morbidities also varied by age. In
the ,15 y model, diarrhea, wasting and severe anemia also
contributed to a large proportion of the S. japonicum disability weight,
in addition to mild/moderate hepatomegaly and splenomegaly. In
contrast, major organ pathologies were the most important variables
in the older cohort model, including mild/moderate hepatomegaly,
mild cirrhosis, and splenomegaly (Table 2).
Sensitivity Analyses
One-way. The overall model was sensitive to probability
estimates for mild/moderate and severe hepatomegaly, moderate
and severe cirrhosis, and splenomegaly; and disability weight
estimates for mild/moderate and severe hepatomegaly and mild
fibrosis (Figure 3). As expected, the one-way sensitivity analyses
varied by age. The ,15 y model was most sensitive to probability
and disability estimates for mild/moderate hepatomegaly and
splenomegaly and to additional disability weight estimates for
wasting and severe anemia. The $15 y model was also sensitive to
probability and disability estimates for mild/moderate hepato-
megaly, mild cirrhosis, and splenomegaly, and to the additional
disability weight for moderate fibrosis.
Multi-way. Considering the most conservative estimate for
each variable simultaneously resulted in a disability weight of
0.047 in the overall model, with age-specific estimates of 0.033 in
the ,15 y model, and 0.091 in the $15 y model. In the
pessimistic scenario, we observed a maximum overall disability
weight of 0.228, which ranged from 0.194 (,15 y) to 0.305
($15 y) in age-specific cohort analyses.
Probabilistic. Findings from probabilistic sensitivity analyses
confirmed the magnitude and robustness of estimates from
deterministic analyses. In the overall model, the average disability
weight was 0.132 over 5,000 Monte Carlo simulations, with age-
specific estimates of 0.098 (,15 y) and 0.186 ($15 y). No
simulations produced disability weight estimates lower than 0.009,
and only 2.5% of simulations in the ,15 y model were less than
0.044. Median values were 0.124 (2.5–97.5%: 0.080–0.232) for all
ages, with age-specific estimates ranging from 0.092 (,15 y; 2.5–
97.5%: 0.044–0.174) to 0.180 ($15 y; 2.5–97.5%: 0.123–0.287)
(Figure 4).
Discussion
Our findings indicate that age-specific disability weights of
0.098 to 0.186 would be a more appropriate estimate for the
burden of human disease due to S. japonicum infection. It is
noteworthy that even the most conservative estimates were seven
times greater than current GBD disability weights for schistoso-
miasis (Table 3) [23,25–27].
Findings in this study are consistent with King et al.’s [19] meta-
analysis of disability-related outcomes in all strains of schistoso-
miasis. Minimum re-estimated disability weights in our assessment
of 0.044 (,15 y) and 0.123 ($15 y) were similar in magnitude to
King et al’s estimates of 0.02 to 0.15, although our median values
Table 2. Proportion of model disability weight attributable to each morbidity
Overall ,15 $15
Contribution to
model disability
weight
% of total
disability weight
(0.130)
Contribution to
model disability
weight
% of total
disability weight
(0.098)
Contribution to
model disability
weight
% of total
disability weight
(0.186)
Diarrhea 0.010 8 0.014 14 0.004 2
Gastrointestinal bleeding 0.010 8 0.001 1 0.001 1
Abdominal pain 0.009 7 0.007 7 0.009 5
Mild/moderate hepatomegaly 0.014 11 0.018 18 0.023 12
Severe hepatomegaly 0.015 12 0.007 7 0.011 6
Mild fibrosis 0.014 11 0.008 8 0.005 3
Moderate fibrosis 0.006 5 0.003 3 0.015 8
Severe fibrosis 0.003 2 0.001 1 0.010 5
Mild cirrhosis 0.013 10 0.000 0 0.054 27
Moderate cirrhosis 0.006 5 0.000 0 0.013 7
Severe cirrhosis 0.006 5 0.000 0 0.006 3
Splenomegaly 0.014 11 0.015 15 0.014 7
Cognitive deficits 0.001 1 0.002 2 0.001 1
Stunting 0.001 1 0.006 6 0.000 0
Wasting 0.002 2 0.011 11 0.000 0
Mild anemia 0.000 0 0.000 0 0.000 0
Moderate anemia 0.001 1 0.002 2 0.001 1
Severe anemia 0.005 4 0.010 10 0.005 3
CNS disease 0.002 2 0.000 0 0.001 1
Epilepsy 0.002 2 0.000 0 0.003 2
doi:10.1371/journal.pntd.0000158.t002
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with the assertion that S. japonicum is more pathogenic than other
schistosomes [22]. Our disability weight estimates are also
consistent with findings from a community-based study in China
that focused on chronic schistosomiasis japonica, reporting an
overall disability weight of 0.191 and age-specific estimates of
0.095 (5–14 y) and 0.159 (15–44 y) [16]. Current findings and
burden re-assessments by King and colleagues and Jia and
colleagues are in contrast to two earlier reviews that suggested a
minimal public health impact of schistosomiasis [34,35].
There are several differences in King et al.’s meta-analysis of all
schistosomes [19]andtheChinastudyfocusingon chronicinfections
due to S. japonicum [16] compared to our analysis, particularly
regarding the selection of schistosomiasis-related health conditions.
In contrast to King et al.’s [19] assessment, we accounted for hepato-
splenic pathologies due to S. japonicum infection, and identified them
as critical disability-related outcomes, as did the Chinese study [16].
The exclusions of organ pathologies in King et al.’s assessment [19]
and nutritional morbidities in the China study [16] may contribute
to an underestimation of disability weights, relative to our findings.
We also excluded work and school performance outcomes in our
assessment, due to the limited availability of such studies in S.
japonicum and a lack of objective standardized measures for these
outcomes. Inclusion of these functional outcomes in future studies is
expected to further increase estimated disability weights for S.
japonicum.
There are several study limitations. Few incidence studies were
available, and results are based on review of only 34 primary
papers (48 total) with usable outcome information. Due to the
nature of this analysis, which is to describe the natural history of
acute and chronic S. japonicum infection, we decided not to formally
score each study based on the quality of the information included.
Hence, we assumed that every report represented the best
available information for the specified population and outcomes
at the time the study was undertaken [31]. Our analysis was
limited by the research designs and topical foci of earlier studies.
We did not include the entire range of possible morbidities and
disabilities due to S. japonicum infection. We also excluded
mortality-related outcomes and did not account for treatment
status, co-morbidities with other infectious or non-infectious
diseases, infection intensity, re-infection, or disease progression
in order to facilitate comparability of findings to the GBD
assessment [23,25–27]. There is a possibility of publication bias in
every review. To limit this, we solicited both published and
unpublished manuscripts and consulted with experts in order to
limit publication bias, and intentionally biased our model estimates
to the lower ranges for each model parameter, in order to obtain
conservative estimates. In addition, when more than one
publication described the frequency of occurrence of a specific
morbidity associated with schistosomiasis, the most conservative
estimate was included in the assessment. These exclusions and
limitations in available studies would likely lead to an underesti-
mation of re-estimated model disability weights.
In schistosomiasis-endemic regions, polyparasitism, malnutri-
tion, and other infectious diseases are ubiquitous. Therefore, it is
important to interpret findings in the context of concurrent
infections. For example, some disability-related outcomes, includ-
ing anemia and diarrhea, may be due to the presence of other
Figure 3. One-way sensitivity analysis. The horizontal bars depict the effect of re-evaluating the disability weight (shown on the X-axis) after
changing the value of the specified parameter from the low to the high end of its range. The number of parameters that resulted in the greatest
variation are shown.
doi:10.1371/journal.pntd.0000158.g003
Figure 4. Probabilistic sensitivity analyses. Boxplots depicting the
resultsof 5,000simulation MonteCarlo analysis for eachage-group model.
Boxes represent the median, 25
th and 75
th percentiles, and error bars
extend to the 2.5
th and 97.5
th percentile. Meansare depictedbythe circles.
doi:10.1371/journal.pntd.0000158.g004
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ed to an over-estimation of disability weights attributable to S.
japonicum, this is unlikely since we used highly conservative estimates
in this analysis. Recent studies have challenged the ability of experts
to quantify patient-centered disability, particularly in chronic
conditions characterized by low mortality [17,19,36,37] and
extensive co-morbidities [19,38,39]. However, the extent of the
disparity between expert opinion and patient’s experience is
unknown. Expert panel methodologies may also underestimate the
disability-related impact of nutritional morbidities, in favor of more
standardized and observable organ pathologies. Therefore, the
fundamental reliance on GBD disability weights in this assessment
also represents an important study limitation.
Decision model estimation is a useful analytic method for
conducting disease burden assessments; however, deterministic
and probabilistic sensitivity analyses are exploratory, rather than
explanatory. As a result, decision model estimation does not
facilitate evaluation of the statistical significance or robustness of
findings, which represents a study limitation. The b-distribution
was selected for this analysis based on its satisfaction of a priori
requirements to restrict the estimate ranges from 0 and 1,
calculation and summarization of data, and evaluation of the level
of estimate uncertainty [32]. Similar to other distributions, the b-
distribution is influenced by the quality, availability, and level of
skewness in model inputs. Therefore, availability and quality of
epidemiological and disease burden data remain study limitations.
Further research is needed to examine the broad range of
morbidities associated with schistosomiasis, particularly on meth-
ods to parse attributable causation of specific infections in the
context of polyparasitism and other comorbid conditions.
Additionally, the separation between specific causes of disease
from associated morbidities, and the exclusion of selected
conditions partially attributable to other infections in the GBD
assessment may contribute to an underestimation of disability
weights for schistosomiasis.
Lastly, as a zoonotic disease, schistosomiasis japonica is also a
veterinary and agricultural public health issue. Future interdisci-
plinary research should consider the direct impact on human
health and the indirect impact on animal health and economic
productivity. Methods described by Budke et al. [40] and Carabin
et al. [41] could also be utilized to broaden S. japonicum burden
assessment to incorporate cost-effectiveness measures [40–42].
In conclusion, a minimum disability weight of 0.033 to 0.091
would be a more accurate estimate of disability due to S. japonicum.
GBD methodologies underestimate the burden of disease
attributable to S. japonicum, and hence they should be revised.
Even a minimal increase in current estimates would result in a
substantial rise in the estimated global burden of schistosomiasis,
and have considerable implications for public health prioritization,
health policy, and resource allocation for research, monitoring,
and control.
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